Skip to main content

Advertisement

Table 4 Baseline Characteristics of the cohort/all patients

From: Low molecular weight heparins use in pregnancy: a practice survey from Greece and a review of the literature

Characteristic N = 818
Age (mean ± SD, median, q25-q75) 33.86 ± 4.85, 34, 31–37
BMI (mean ± SD, median, q25-q75) 24.5 ± 4, 23.64, 21.87–26.18
No. of foetuses at observed gestation (N, % and 95 CI)
 1 767 (93.77%, CI: 91.90–95.23%)
  ≥ 2 51 (6.23%, CI: 4.77–8.10%)
Delivery by CS (N, %) 644 (78.7)
Reason for enrolling in the study
 Group A: History of VTE (DVT/SVT/Arterial thrombosis/Arterial Ischemia) 76 (9.29%, CI: 7.49–11.47%)
 Group B: History of Pregnancy complications 445 (54.40%, CI: 50.97–57.78%)
  Early pregnancy losses 396 (88.99%, CI: 85.74–91.57%)
  Pregnancy losses < 3–3 or more 348–48
  IUGR 10 (2.25%, CI: 1.23–4.09%)
  Fetal death 28 (6.29, CI: 4.39–8.94%)
  Pre-eclampsia/eclampsia 10 (2.25%, CI: 1.23–4.09%)
  Preterm labor/placenta abruption 1 (0.22%, CI: 0.04–1.25%)
 Group C: IVF 132 (16.14%, CI: 13.78–18.82%)
 Group D: Other reasons 165 (20.17%, CI: 17.56–23.06%)
  Family History of VTE 73 (44.24%, CI: 36.88–51.96%)
  Asymptomatic Hereditary Thrombophilia 45 (27.27%, CI: 21.05–34.52%)
  Increased resistance in uterine arteries 2 (1.21%, CI: 0.03–4.31%)
  Reasons not specified 45 (27.27%, CI: 21.05–34.52%)
Mean Duration of LMWH (months) (mean ± SD, median, q25-q75) 8.63 ± 1.49, 9, 9–9.5
Concomitant Use of ASA (N, % and 95 CI) 152 (18.58%, CI: 16.06–21.39%)
Mean Duration of ASA (months) (mean ± SD, median, q25-q75) 6.21 ± 2.56, 7, 3–8